Zak Mir takes a charting look at S&P 500, Nasdaq 100, Adaptimmune, Aeries, AquaBounty, American Battery, Cardylytics, Laser Photonics, Intellia, Psyence, Qualigen, and Rock Mountain.
In this update, I walk through the S&P 500 and Nasdaq 100 technical picture, then run through a watchlist of individual US stocks showing potential setups. Below are the key levels, trend-channel targets and the short-term scenarios I’m watching. Use these as a roadmap for what I expect over the coming days and into next month.
As always, do your own research and treat these as chart-based observations rather than hard recommendations.
Market overview
S&P 500
The S&P remains inside the rising trend channel that began in April. The upside target from the channel projection is near 6,775 , which is the level I’d normally expect by the end of next month (and possibly sooner given recent momentum).
Key support/resistance levels to watch:
- Immediate support / old September resistance: 6,540 — tested recently and should hold in the near term while we probe higher.
- Floor of the channel (worst case short-term): 6,400 if we break below 6,540.
Nasdaq 100
The Nasdaq 100 is stretching toward the top of its rising channel from April. Near-term targets:
- Top of current channel: ~25,000 — look for this by the end of the month.
- Next resistance projection: ~26,000 — a likely target by the end of next month (resistance line projection from late January).
Downside guards:
- Around 24,000 looks like a lower limit in the short run.
- Worst case would be a re-test of the channel floor near 23,300 .
Overall the technical tilt is north, helped by a gap-up move that created a failed gap-fill to the downside yesterday — a bullish sign.
Stock watch
Below are the names I covered and the technical levels and patterns I’m watching for each. Targets are short-term (days to a month) and refer to daily chart features, moving averages, channel tops and common reversal patterns.
Adaptimmune Therapeutics
- Pattern: U-shaped bottom / base-turnaround after a July gap down and a gap up earlier this month.
- 50-day line acts as support around $0.12 — stay on the right side of that level.
- Targets: up to $0.25 by the end of this month; best case toward $0.35 (200-day and the July peak) by the end of next month.
Aerie Technology
- We saw a brief break below the rising channel floor near $0.72 , just under the 200-day ($0.76).
- Ideal scenario is holding above the 200-day ($0.76) and moving back toward the channel top near $1.65 by end of next month.
- RSI shows bullish divergence (lower lows in price with higher RSI traces) — a classic turnaround signal.
Aquabounty Technologies
- Following the rising trend channel — short-term target near the channel top around $1.60
- Given recent strength, a move toward $1.80+ by the end of this month is on the table while price remains above yesterday’s support near $1.32 (close basis).
American Battery
- The stock is aligned with the uptrend inside the rising channel from December.
- Top of that channel projects up near $4.50 — a potential target by the end of next month while price stays above the 50-day ($2.43 ).
- Near-term support/resistance cluster: $2.60–2.70 before a push higher.
Cardlytics
- Forming a broadening triangle base. Top of the triangle points toward about $4.00 , a target I’d expect by the end of next month if the pattern resolves upward.
- Keep it above the 200-day ( $2.24 ) for the bullish scenario to remain intact.
Laser Photonics
- Also in a broadening triangle and has gapped through the 200-day ($3.11 ).
- With the breakout, look for the triangle top near $8.50 by the end of next month.
- The rising 50-day is providing support while the gap through the 200-day is constructive.
Intellia Therapeutics
- Inside a clean rising trend channel with the 50-day as the base ($11.77 ).
- Top of the channel projects toward roughly $21 by the end of next month.
- Important support to watch: the old July peak near $14.60 on a close basis. RSI has shown 50-level rebounds recently.
Science Biomedical
- Base forming in a broadening triangle. The nominal top of the triangle aligns with the 200-day area ($7.70 ).
- Maintain above the 50-day ($4.43 ) on a close basis to keep the upside case valid.
- RSI bounced above the neutral 50 level and there’s a bullish gap supporting higher odds of continuation.
Qualigen Therapeutics
- Dynamic reversal pattern — gap through the 50-day ($2.27 ) and a W-shaped daily reversal.
- RSI 50-level rebound and momentum suggest stronger near-term upside.
- Short-term target: the recent range top around $3.65 , possibly in the coming days or by month-end.
Rocky Mountain
- Rising trend channel in play — channel top projects to about $2.90 by the end of next month.
- Support in recent sessions around $1.80 (just below yesterday’s support). RSI has rebounded above 50.
- Failed gap-fill earlier in the week acts as a bullish sign; price action favors the upside while support holds.
What I’m watching next
- Risk management: watch the key support levels and moving averages mentioned above on end-of-day closes.
- Channel tops as targets: many names are pointing toward trend-channel ceilings in the next few weeks — use them as reference targets, not hard ceilings.
- RSI behavior: several stocks show RSI rebounds above 50 or bullish divergence — these validate the turnarounds but need confirmation by price staying above supportive moving averages.
That’s it for today. I’ll be monitoring these levels and setups over the weekend and into next week — expect more updates as the picture evolves.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
